A5036049219- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Diagnosis and Treatment
- Radiation Dose and Imaging
- Prostate Cancer Treatment and Research
- Advanced X-ray and CT Imaging
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Artificial Intelligence in Healthcare and Education
- Sarcoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Esophageal Cancer Research and Treatment
- Cancer, Hypoxia, and Metabolism
- Radiology practices and education
- Advanced Radiotherapy Techniques
- Breast Cancer Treatment Studies
- AI in cancer detection
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies
- Bone health and treatments
- Cancer Diagnosis and Treatment
Baylor College of Medicine
2016-2025
Charles Sturt University
2021-2025
Methodist Hospital
2024
Radiology Associates
2024
American College of Radiology
2024
Cambridge University Hospitals NHS Foundation Trust
2020
The University of Texas MD Anderson Cancer Center
2009-2019
Medanta The Medicity
2017
Society of Nuclear Medicine and Molecular Imaging
2017
Fundação de Amparo à Pesquisa do Estado de São Paulo
2016
In the late 1980s and early 1990s, number of newly diagnosed prostate cancers in United States increased dramatically, surpassing lung cancer as most common men. 1 Experts generally believe that these changes resulted from prostate-specific antigen (PSA) screening detected many earlystage cancers.For example, percentage patients with low-risk disease has (45.3% 1999-2001 vs. 29.8% 1989-1992; P < .0001). 2 The incidence 2.0% annually 1995 to 2001 since declined.In 2009, an estimated 192,280...
These NCCN Guidelines Insights focus on recent updates to the 2015 for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it important test tumor tissue from determine whether they alterations that make them candidates therapies. describe different testing methods currently available determining 2 most commonly actionable alterations, notably anaplastic lymphoma kinase (ALK) gene...
These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was subject a major update in 2013 Clinical Practice Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The updates and discuss new greater detail.
Purpose To determine whether a response classification based on integration of fluorine-18–fluorodeoxyglucose positron emission tomography (FDG-PET) into the International Workshop Criteria (IWC) provides more accurate assessment than IWC alone in patients with non-Hodgkin's lymphoma (NHL). Patients and Methods Fifty-four aggressive NHL who underwent FDG-PET computed 1 to 16 weeks after four eight cycles chemotherapy cyclophosphamide, doxorubicin, vincristine, prednisone were assessed for...
Most patients with non–small cell lung cancer (NSCLC) are diagnosed advanced cancer. These guidelines only include information about stage IV NSCLC. Patients widespread metastatic disease (stage IV) candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify before initiating aggressive treatment, thus sparing these from unnecessary futile If discovered during surgery, then extensive surgery often aborted. Decisions treatment should be based on...
Prostate cancer has surpassed lung as the most common in men United States. The NCCN Guidelines for Cancer provide multidisciplinary recommendations on clinical management of patients with prostate based evidence and expert consensus. Panel guidance treatment decisions localized disease is represented this version. Significant updates early include distinction between active surveillance observation, a new section principles imaging, revisions to radiation recommendations. full version these...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations the clinical management of patients with prostate cancer. These Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents new standard care metastatic castration-recurrent cancer who have previously received docetaxel (category 1 recommendation). also category 2B prechemotherapy setting asymptomatic or...
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion the guidelines focuses on use systemic therapy in disease. colorectal cancer involves a continuum care which patients are exposed sequentially to variety active agents, either combinations or as single agents. Choice is based goals type timing prior therapy, different...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) focuses on principles of radiation therapy (RT), which include following: (1) general early-stage, locally advanced, and advanced/metastatic NSCLC; (2) target volumes, prescription doses, normal tissue dose constraints advanced/palliative RT; (3) RT simulation, planning, delivery. Treatment recommendations should be made by a multidisciplinary team, including...
The NCCN Guidelines for Rectal Cancer begin with the clinical presentation of patient to primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management recurrent metastatic disease, survivorship. Panel meets at least annually review comments from reviewers within their institutions, examine relevant new data publications abstracts, reevaluate update recommendations. These Insights...
The aim of our study was to retrospectively evaluate whether maximum standardized uptake value (SUV(max)), total lesion glycolysis (TLG), or change therein using (18)F-FDG PET/CT performed before and after initial chemotherapy were indicators patient outcome.Thirty-one consecutive patients who underwent chemotherapy, followed by tumor resection, reviewed. Univariate Cox regression used analyze for relationships between covariates interest (SUV(max) in SUV(max), TLG TLG, necrosis)...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer begin with the clinical presentation of patient to primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management recurrent metastatic disease, survivorship. Panel meets annually review comments from reviewers within their institutions reevaluate update recommendations. In addition, panel has interim conferences...
These NCCN Clinical Practice Guidelines in Oncology provide recommendations for the management of rectal cancer, beginning with clinical presentation patient to primary care physician or gastroenterologist through diagnosis, pathologic staging, neoadjuvant treatment, surgical management, adjuvant surveillance, recurrent and metastatic disease, survivorship. This discussion focuses on localized disease. The Rectal Cancer Panel believes that a multidisciplinary approach, including...
Circulating tumor cells (CTCs) and [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed (CT) are two new promising tools for therapeutic monitoring. In this study, we compared the prognostic value of CTC FDG-PET/CT monitoring during systemic therapy metastatic breast cancer (MBC).A retrospective analyses 115 MBC patients who started a line had counts scans performed at baseline 9 to 12 weeks (midtherapy) was performed. Patients were categorized according midtherapy as...
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval treatment symptomatic bone metastases and no known visceral disease. It category 1 recommendation as both first-line second-line option. Panel also revised choice intermittent or continuous androgen deprivation...
The purpose of this study was to evaluate outcome after <sup>223</sup>Ra dichloride therapy (<sup>223</sup>Ra) and determine whether skeletal tumor burden on whole-body <sup>18</sup>F-fluoride PET/CT can be used as a predictive biomarker survival in patients treated with <sup>223</sup>Ra. <b>Methods:</b> Forty-two hormone-refractory prostate cancer underwent baseline fluoride scan. Fluoride parameters were generated, including maximum standardized uptake value (SUV<sub>max</sub>) the hottest...
Mammalian target of rapamycin (mTOR) inhibitors mediate AKT activation through a type 1 insulin-like growth factor receptor (IGF-1R)-dependent mechanism. Combining the mTOR inhibitor temsirolimus with cixutumumab, fully human immunoglobulin G1 monoclonal antibody directed against IGF-1R, was expected to enhance mTOR-targeted anticancer activity by modulating resistance inhibition. The objectives this phase I study were evaluate tolerability and cixutumumab.Patients in sequential cohorts ("3...